Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 

       2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved

Octreotide Acetate top

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Octreotide Acetate Manufacturers in India Suppliers Octreotide Acetate Dossage Exporters Distributors Octreotide Acetate api active pharmaceuticals ingredients Octreotide Acetate manufacturers Side Effects bulk drugs raw material Dossage Octreotide Acetate companies Side Effects Dossage Importers Octreotide Acetate Dossage Octreotide Acetate Exporters Octreotide Acetate exporters Dossage FDA Dossage Octreotide Acetate Dossage DMF Symptoms Dossage Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Octreotide Acetate manufacturing pharmaceutical drugs pharmaceutical intermediates Octreotide Acetate pharmaceutical chemicals pharmaceutical raw materials Octreotide Acetate active pharmaceutical ingredients Octreotide Acetate committee active pharmaceutical ingredients manufacturer Octreotide Acetate Active Pharmaceutical Ingredients manufacturer Octreotide Acetate exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Octreotide Acetate, Octreotide Acetate manufacturer India, Octreotide Acetate product, Octreotide Acetate products, Api preparation, Certificate of Analysis API manufacturer product, Octreotide Acetate anti ulcer product, Certificate of Origin COA Octreotide Acetate COS Octreotide Acetate, pharmaceutical generic, pharmaceutical drug, medical, Octreotide Acetate pharma healthcare, pharma patents, contract MSDS manufacturing Trader Octreotide Acetate pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Octreotide Acetate expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Octreotide Acetate DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Octreotide Acetate ingredients, api, HIV Octreotide Acetate, tablets, capsules, syrup & protein Octreotide Acetate powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Octreotide Acetate gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Octreotide Acetate WHO, UKMHRA Approval

   API >>>
   Pharmaceuticals API List
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us

Octreotide Acetate left





HOME >> API >> API List 3 >> Octreotide Acetate >> Dosage

Octreotide Acetate CAS Registry Number 79517-01-4

Octreotide Acetate CAS Registry Number 79517-01-4

Withdraw octreotide yearly for approximately 4 wk from patients who received irradiation to assess disease activity. If GH or IGF-1 levels increase and signs and symptoms recur, therapy may be resumed.

IV / Subcutaneous 50 mcg 3 times daily. Although 100 mcg 3 times daily is the most commonly effective dosage, some patients require up to 500 mcg 3 times daily.
Patients not currently receiving octreotide

Before administering the octreotide long-acting depot formulation , patients not currently receiving octreotide should begin therapy with octreotide immediate-release formulation  given subcutaneously in an initial dosage of 50 mcg 3 times daily. Most patients require 100 to 200 mcg 3 times daily, but some patients require 500 mcg 3 times daily. After maintaining patients on subcutaneous octreotide for at least 2 wk to determine tolerance, patients who are considered responders can be switched to administration of the intragluteal long-acting depot formulation in a dose of 20 mg given IM intragluteally at 4-wk intervals for 3 months; dosage may be adjusted as follows:
GH 2.5 ng/mL or less, IGF-1 normal and clinical symptoms controlled

Maintain octreotide depot dosage at 20 mg every 4 wk.
GH greater than 2.5 ng/mL, IGF-1 elevated and/or clinical symptoms uncontrolled

Increase the octreotide depot dosage to 30 mg every 4 wk.
GH 1 ng/mL or less, IGF-1 normal and clinical symptoms controlled

Reduce the octreotide depot dosage to 10 mg every 4 wk.
GH, IGF-1, or symptoms are not adequately controlled at a dose of 30 mg

The dosage may be increased to 40 mg every 4 wk. Higher doses are not recommended.
Dosage adjustments after 2 months

If symptoms are adequately controlled, consider a dose reduction to 10 mg for a trial period. If symptoms recur, dosage should be increased to 20 mg every 4 wk. If symptoms are not adequately controlled, increase the octreotide long-acting depot dose to 30 mg every 4 wk. Patients who achieve good control on a 20 mg dose may have their dose lowered to 10 mg for a trial period. If symptoms recur, increase the dosage to 20 mg every 4 wk. Doses higher than 30 mg are not recommended. Patients with carcinoid tumors and VIPomas who experience periodic exacerbation of symptoms, whether they are being maintained on the immediate-release or long-acting depot formulation, may be given subcutaneous immediate-release injections for a few days at the dosage they were receiving prior to switching to the depot formulation. When symptoms are controlled, the subcutaneous injections may be discontinued.

Information Associated with Product:
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj Pharmaceuticals API Logo

Octreotide Acetate

Api Manufacturer,Export,Supplies,Manufacturing in India

Copyright Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap


    Investor Relations    Feedback     Contact Worldwide    Sitemap


taj group logo
2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Limited  products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.